Epsilogen
Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.
London, UKepsilogen.com ↗
Total raised
€37M
€36,980,247
Funding rounds
1
Investors
5
distinct backers
Active since
2022-03
latest 2022-03
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood35
base rate 48% for Series B
- ▼ Overdue vs cohort gap
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-03-02 | Series B | €37M | 3B Future Health Fund,British Patient Capital,Caribou Property,Novartis Venture Fund,Schroders Capital | View deal → |